logo
Plus   Neg
Share
Email

Sorrento Gets FDA Approval For Phase 1 Study For COVID Treatment; Shares Up 5%

Shares of Sorrento Therapeutics Inc. (SRNE) gained over 5% in extended trading session on Tuesday after the company FDA cleared its Investigational New Drug application for early stage study of STI-2099 in both healthy volunteers and COVID-19 patients.

Sorrento Therapeutics said it received clearance from the FDA for its Investigational New Drug application for its Phase 1 study of the safety and pharmacokinetics of intranasal STI-2099 (COVIDROPS) in both healthy volunteers and patients with mild COVID-19.

Sorrento is currently evaluating an intravenous formulation of this potent antibody, STI-2020 (IV), in a Phase 1 study in healthy volunteers and COVID-19 patients with mild symptoms.

"We plan to use our intranasal formulation technology, which allows administering a drug via simple drops in the nose, for other antibodies we are currently developing with a goal of providing coverage against all variants of the SARS-CoV-2 virus that might evade inhibition from treatment with existing therapies," said Dr. Henry Ji, Chairman and CEO of Sorrento.

SRNE closed Tuesday's trading at $9.44, down $0.81 or 7.90%, on the Nasdaq. The stock, however, gained $0.56 or 5.93% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC. Morgan Stanley (MS) reported a first-quarter profit that more than doubled from last year, reflecting strong performance across all of its business segment. Net revenues for the quarter grew 61 percent from the previous year. Quarterly adjusted earnings per share beat analysts' estimates.
Follow RTT